Stay updated with breaking news from Mark Throsby. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Gadeta B.V. ('Gadeta'), a clinical-stage company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for every...
/PRNewswire/ -- Gadeta B.V. ('Gadeta'), a clinical-stage company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for every...
/PRNewswire/ -- Gadeta B.V. ('Gadeta'), a clinical-stage company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for every...
- Aim is to develop gamma delta (?d) T-cell receptor (TCR)-based immunotherapies for solid tumors - Ph1/2 update on lead product GDT002 as well as nomination of second pipeline program
Gadeta announces significant progress in advancing pipeline and TEG platform development · Aim is to develop gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for solid tumors· Ph1/2 update on lead product GDT002 as...